View in EDS HTML Full Text PDF Full Text

Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial.

Saved in:
Bibliographic Details
Title: Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial.
Authors: Gao Y; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia., Cheng AL; National Taiwan University Cancer Center, Taipei, Taiwan., Li LX; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia., Parent N; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia., Kichenadasse G; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.; Department of Medical Oncology, Flinders Medical Centre, Adelaide, Australia., Karapetis CS; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.; Department of Medical Oncology, Flinders Medical Centre, Adelaide, Australia., Rowland A; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia., Hopkins AM; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia., Sorich MJ; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Source: International journal of cancer [Int J Cancer] 2025 Jul 15; Vol. 157 (2), pp. 336-344. Date of Electronic Publication: 2025 Mar 13.
Publication Type: Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40079683
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gao+Y%22">Gao Y</searchLink>; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.<br /><searchLink fieldCode="AU" term="%22Cheng+AL%22">Cheng AL</searchLink>; National Taiwan University Cancer Center, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Li+LX%22">Li LX</searchLink>; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.<br /><searchLink fieldCode="AU" term="%22Parent+N%22">Parent N</searchLink>; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.<br /><searchLink fieldCode="AU" term="%22Kichenadasse+G%22">Kichenadasse G</searchLink>; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.; Department of Medical Oncology, Flinders Medical Centre, Adelaide, Australia.<br /><searchLink fieldCode="AU" term="%22Karapetis+CS%22">Karapetis CS</searchLink>; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.; Department of Medical Oncology, Flinders Medical Centre, Adelaide, Australia.<br /><searchLink fieldCode="AU" term="%22Rowland+A%22">Rowland A</searchLink>; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.<br /><searchLink fieldCode="AU" term="%22Hopkins+AM%22">Hopkins AM</searchLink>; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.<br /><searchLink fieldCode="AU" term="%22Sorich+MJ%22">Sorich MJ</searchLink>; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220042124%22">International journal of cancer</searchLink> [Int J Cancer] 2025 Jul 15; Vol. 157 (2), pp. 336-344. <i>Date of Electronic Publication: </i>2025 Mar 13.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Liss%22">Wiley-Liss </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0042124 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0215 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200207136%22">00207136 </searchLink><i>NLM ISO Abbreviation: </i>Int J Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40079683
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/ijc.35407
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 336
    Titles:
      – TitleFull: Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gao Y
      – PersonEntity:
          Name:
            NameFull: Cheng AL
      – PersonEntity:
          Name:
            NameFull: Li LX
      – PersonEntity:
          Name:
            NameFull: Parent N
      – PersonEntity:
          Name:
            NameFull: Kichenadasse G
      – PersonEntity:
          Name:
            NameFull: Karapetis CS
      – PersonEntity:
          Name:
            NameFull: Rowland A
      – PersonEntity:
          Name:
            NameFull: Hopkins AM
      – PersonEntity:
          Name:
            NameFull: Sorich MJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 07
              Text: 2025 Jul 15
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1097-0215
          Numbering:
            – Type: volume
              Value: 157
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: International journal of cancer
              Type: main
ResultId 1